히스톤 탈아세틸화효소 억제제 시장 보고서(2026년)

Histone deacetylase inhibitors are a category of compounds that block the activity of histone deacetylases, which are enzymes responsible for removing acetyl groups from histone proteins. By inhibiting these enzymes, histone acetylation levels increase, resulting in a more relaxed chromatin structure and changes in gene expression.

The main classification types of histone deacetylase inhibitors include Class I histone deacetylases (HDACs), Class II histone deacetylases (HDACs), Class III histone deacetylases (HDACs), and others. Histone deacetylases are a group of enzymes that remove acetyl groups from histone proteins, causing chromatin to condense and suppress gene transcription. These inhibitors can be administered through oral and injectable routes and are distributed via hospital pharmacies, online pharmacies, retail pharmacies, and other channels. They are used across various applications, including oncology, neurology, and others, with end users such as hospitals, home care settings, specialty clinics, and others.

Tariffs have impacted the histone deacetylase inhibitors market by increasing the cost of imported active pharmaceutical ingredients, chemical intermediates, and specialized laboratory equipment used in drug development and manufacturing. These impacts have been most evident in oncology-focused HDAC inhibitor segments, particularly in North America and Europe where complex synthesis often relies on global supply chains. Asia-Pacific manufacturers have experienced cost fluctuations due to trade dependencies. However, tariffs have encouraged localized synthesis capabilities and domestic manufacturing investments, supporting long-term supply chain resilience.

The histone deacetylase inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase inhibitors market statistics, including histone deacetylase inhibitors industry global market size, regional shares, competitors with a histone deacetylase inhibitors market share, detailed histone deacetylase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. This histone deacetylase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.29 billion in 2025 to $1.39 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to early success of hdac inhibitors in hematological malignancies, growing understanding of epigenetic regulation in disease, availability of approved first-generation hdac inhibitors, expansion of cancer research infrastructure, increased investment in targeted cancer therapies.

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising global cancer incidence, growing pipeline of epigenetic-based therapies, increasing focus on precision oncology approaches, expansion of clinical trials for neurological and inflammatory indications, demand for more selective and safer epigenetic drugs. Major trends in the forecast period include increasing use of hdac inhibitors in oncology treatment regimens, growing focus on selective and isoform-specific hdac inhibitors, rising adoption of combination therapies involving hdac inhibitors, expansion of hdac inhibitor research beyond cancer indications, steady growth in oral hdac inhibitor formulations.

The rising incidence of cancer is expected to drive the growth of the histone deacetylase inhibitors market in the coming years. The increasing occurrence of cancer is mainly attributed to aging populations, greater exposure to risk factors such as tobacco use, dietary habits, and environmental pollutants, as well as improved diagnostic methods that enable earlier and more frequent detection. Histone deacetylase inhibitors are used in cancer treatment by modifying chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, thereby triggering cell cycle arrest and apoptosis in cancer cells. For example, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, around 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases reported in 2022. Hence, the growing incidence of cancer is fueling the expansion of the histone deacetylase inhibitors market.

Major companies operating in the histone deacetylase inhibitors market are emphasizing the development of innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to broaden treatment options and enhance patient convenience and adherence. An oral histone deacetylase inhibitor is a medication administered by mouth that targets HDAC enzymes involved in gene regulation and may be used to treat various conditions, including cancer and inflammatory diseases. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received approval from the Food and Drug Administration for Duvyzat (givinostat), an oral histone deacetylase inhibitor, for treating Duchenne muscular dystrophy (DMD) in patients aged six years and older. Duvyzat works by mitigating the cascade of events that lead to muscle damage, potentially slowing the progression of muscle degeneration associated with DMD. By inhibiting excessive HDAC activity, it helps reduce inflammation and fibrosis while supporting muscle fiber regeneration. The approval was based on results from the pivotal phase 3 EPIDYS trial, which achieved its primary endpoint by showing a statistically significant reduction in the time required to complete the four-stair climb test compared to placebo.

In January 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition is intended to strengthen and diversify Bristol Myers Squibb's oncology portfolio, which includes the commercial lung cancer drug KRAZATI (adagrasib) and a robust KRAS-focused development program with two Phase 1 candidates. The move aims to accelerate the development and delivery of innovative cancer therapies and support the company's long-term growth in oncology. Mirati Therapeutics Inc. is a US-based targeted oncology company focused on developing cancer treatments, including histone deacetylase inhibitors.

Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.

North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the histone deacetylase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Histone Deacetylase Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses histone deacetylase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for histone deacetylase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The histone deacetylase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Classification: Class I Histone Deacetylases (HDACs); Class II Histone Deacetylases (HDACs); Class III Histone Deacetylases (HDACs); Other Classifications
• 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 4) By Application: Oncology; Neurology; Other Applications
• 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors; HDAC2 Inhibitors; HDAC3 Inhibitors; HDAC8 Inhibitors
• 2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors; HDAC5 Inhibitors; HDAC6 Inhibitors; HDAC7 Inhibitors; HDAC9 Inhibitors; HDAC10 Inhibitors
• 3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors; Sirtuin 2 (SIRT2) Inhibitors; Sirtuin 3 (SIRT3) Inhibitors; Sirtuin 4 (SIRT4) Inhibitors; Sirtuin 5 (SIRT5) Inhibitors; Sirtuin 6 (SIRT6) Inhibitors; Sirtuin 7 (SIRT7) Inhibitors
• 4) By Other Classifications: Dual-acting HDAC Inhibitors; Pan-HDAC Inhibitors; Selective HDAC Inhibitors; Combination Inhibitors (HDAC + Other Mechanisms)
• Companies Mentioned: Syndax Pharmaceuticals Inc.; MEI Pharma Inc.; Italfarmaco S.p.A.; Shenzhen Chipscreen Biosciences Co. Ltd.; Celgene Corporation; Spectrum Pharmaceuticals Inc.; Curis Inc.; Onxeo SA; Celleron Therapeutics; Forum Pharmaceuticals Inc.; Merck & Co. Inc.; AstraZeneca plc; Novartis AG; Eisai Co. Ltd.; Karyopharm Therapeutics Inc.; Medivir AB; Huya Bioscience International LLC; Crystal Genomics Inc.; Midatech Pharma PLC; Regenacy Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Histone Deacetylase Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Histone Deacetylase Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Histone Deacetylase Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Histone Deacetylase Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of Hdac Inhibitors In Oncology Treatment Regimens
  • 4.2.2 Growing Focus On Selective And Isoform-Specific Hdac Inhibitors
  • 4.2.3 Rising Adoption Of Combination Therapies Involving Hdac Inhibitors
  • 4.2.4 Expansion Of Hdac Inhibitor Research Beyond Cancer Indications
  • 4.2.5 Steady Growth In Oral Hdac Inhibitor Formulations

5. Histone Deacetylase Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Oncology Clinics
• 5.3 Research And Academic Institutes
• 5.4 Homecare Settings
• 5.5 Pharmaceutical Research Laboratories

6. Histone Deacetylase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Histone Deacetylase Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Histone Deacetylase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Histone Deacetylase Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Histone Deacetylase Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Histone Deacetylase Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Histone Deacetylase Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Histone Deacetylase Inhibitors Market Segmentation

• 9.1. Global Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
• 9.2. Global Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Other Routes Of Administration
• 9.3. Global Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
• 9.4. Global Histone Deacetylase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Neurology, Other Applications
• 9.5. Global Histone Deacetylase Inhibitors Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.6. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class I Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
• 9.7. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class II Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
• 9.8. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class III Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
• 9.9. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Other Classifications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

10. Histone Deacetylase Inhibitors Market Regional And Country Analysis

• 10.1. Global Histone Deacetylase Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Histone Deacetylase Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Histone Deacetylase Inhibitors Market

• 11.1. Asia-Pacific Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Histone Deacetylase Inhibitors Market

• 12.1. China Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Histone Deacetylase Inhibitors Market

• 13.1. India Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Histone Deacetylase Inhibitors Market

• 14.1. Japan Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Histone Deacetylase Inhibitors Market

• 15.1. Australia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Histone Deacetylase Inhibitors Market

• 16.1. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Histone Deacetylase Inhibitors Market

• 17.1. South Korea Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Histone Deacetylase Inhibitors Market

• 18.1. Taiwan Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Histone Deacetylase Inhibitors Market

• 19.1. South East Asia Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Histone Deacetylase Inhibitors Market

• 20.1. Western Europe Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Histone Deacetylase Inhibitors Market

• 21.1. UK Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Histone Deacetylase Inhibitors Market

• 22.1. Germany Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Histone Deacetylase Inhibitors Market

• 23.1. France Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Histone Deacetylase Inhibitors Market

• 24.1. Italy Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Histone Deacetylase Inhibitors Market

• 25.1. Spain Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Histone Deacetylase Inhibitors Market

• 26.1. Eastern Europe Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Histone Deacetylase Inhibitors Market

• 27.1. Russia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Histone Deacetylase Inhibitors Market

• 28.1. North America Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Histone Deacetylase Inhibitors Market

• 29.1. USA Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Histone Deacetylase Inhibitors Market

• 30.1. Canada Histone Deacetylase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Histone Deacetylase Inhibitors Market

• 31.1. South America Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Histone Deacetylase Inhibitors Market

• 32.1. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Histone Deacetylase Inhibitors Market

• 33.1. Middle East Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Histone Deacetylase Inhibitors Market

• 34.1. Africa Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Histone Deacetylase Inhibitors Market, Segmentation By Classification, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Histone Deacetylase Inhibitors Market Regulatory and Investment Landscape

36. Histone Deacetylase Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. Histone Deacetylase Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Histone Deacetylase Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Histone Deacetylase Inhibitors Market Company Profiles
  • 36.3.1. Syndax Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. MEI Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Italfarmaco S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Shenzhen Chipscreen Biosciences Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

37. Histone Deacetylase Inhibitors Market Other Major And Innovative Companies

• Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.

38. Global Histone Deacetylase Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Histone Deacetylase Inhibitors Market

40. Histone Deacetylase Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 Histone Deacetylase Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Histone Deacetylase Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Histone Deacetylase Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer